Cancer chemopreventive and therapeutic effects of diosgenin, a food saponin

Nutrition and Cancer

Volumn 61, Issue 1, 2009, Pages 27-35

  Raju, Jayadev ^a   Mehta, Rekha ^a  

^a TOXICOLOGY RESEARCH DIVISION   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIOSGENIN; FATTY ACID; LIPOXYGENASE; NUTRACEUTICAL; PLANT MEDICINAL PRODUCT; PROSTAGLANDIN SYNTHASE; SAPONIN; STEROID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; CANCER GROWTH; CANCER PREVENTION; CARCINOGENESIS; CELL COMMUNICATION; CELL CYCLE; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG INDUSTRY; FOOD; HUMAN; IN VITRO SELECTION; IN VIVO STUDY; LEGUME; METASTASIS; MODULATION; NEOPLASM; PRECURSOR; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY; TRADITIONAL MEDICINE; YAM;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; DIOSGENIN; HUMANS; NEOPLASMS; SAPONINS;

EID: 58149154359     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802357352     Document Type: Review

References (72)

1. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, et al.: Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 12, 3661-3697, 2006.
2. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71, 1397-1421, 2006.
3. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, et al.: Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14, 120-125, 2005.
4. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, et al.: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7, 1894-1900, 2001.
5. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, et al.: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66, 1234-1240, 2006.
6. Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, et al.: Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 12, 383-390, 2003.
7. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al.: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24, 2783-2840, 2004.
8. You WC, Brown LM, Zhang L, Li JY, Jin ML, et al.: Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 98, 974-983, 2006.
9. Shi J, Arunasalam K, Yeung D, Kakuda Y, Mittal G, et al.: Saponins from edible legumes: chemistry, processing, and health benefits. J Med Food 7, 67-78, 2004.
10. Price KR, Johnson IT, and Fenwick GR: The chemistry and biological significance of saponins in foods and feeding stuffs. Crit Rev Food Sci Nutr, 26, 27-135, 1987.
11. Rao AV and Gurfinkel DM: The bioactivity of saponins: triterpenoid and steroidal glycosides. Drug Metab Drug Interact, 17, 211-235, 2000.
12. Taylor WG, Elder JL, Chang PR, and Richards KW: Microdetermination of diosgenin from fenugreek (Trigonella foenum-graecum) seeds. J Agric Food Chem 48, 5206-5210, 2000.
13. Final report of the amended safety assessment of Dioscorea Villosa (Wild Yam) root extract. Int J Toxicol 23, 49-54, 2004.
14. Djerassi C, Rosenkranz G, Pataki J, and Kaufmann S: Steroids, XXVII: synthesis of allopregnane-3∼, 11 beta, 17-, 20∼, 21-pentol from cortisone and diosgenin. J Biol Chem 194, 115-118, 1952.
15. Komesaroff PA, Black CV, Cable V, and Sudhir K: Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 4, 144-150, 2001.
16. McAnuff MA, Harding WW, Omoruyi FO, Jacobs H, Morrison EY, et al.: Hypoglycemic effects of steroidal sapogenins isolated from Jamaican bitter yam, Dioscorea polygonoides. Food Chem Toxicol 43, 1667-1672, 2005.
17. Juarez-Oropeza MA, Diaz-Zagoya JC, and Rabinowitz JL: In vivo and in vitro studies of hypocholesterolemic effects of diosgenin in rats. Int J Biochem 19, 679-683, 1987.
18. Kwon CS, Sohn HY, Kim SH, Kim JH, Son KH, et al.: Anti-obesity effect of Dioscorea nipponica Makino with lipase-inhibitory activity in rodents. Biosci Biotechnol Biochem 67, 1451-1456, 2003.
19. Son IS, Kim JH, Sohn HY, Son KH, Kim JS, et al.: Antioxidative and hypolipidemic effects of diosgenin, a steroidal saponin of yam (Dioscorea spp.), on high-cholesterol fed rats. Biosci Biotechnol Biochem 71, 3063-3071, 2007.
20. Turchan-Cholewo J, Liu Y, Gartner S, Reid R, Jie C, et al.: Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis 23, 109-119, 2006.
21. Yamada T, Hoshino M, Hayakawa T, Ohhara H, Yamada H, et al.: Dietary diosgenin attenuates subacute intestinal inflammation associated with indomethacin in rats. Am J Physiol 273, G355-G364, 1997.
22. Dinarello CA: The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev 25, 307-313, 2006.
23. Raju J, Patlolla JM, Swamy MV, and Rao CV: Diosgenin, a steroid saponin of Trigonella foenum graecum (Fenugreek), inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells. Cancer Epidemiol Biomarkers Prev 13, 1392-1398, 2004.
24. Malisetty VS, Patlolla JMR, Raju J, Marcus LA, Choi CI, et al.: Chemoprevention of colon cancer by diosgenin, a steroidal saponin constituent of fenugreek. Proc Am Assoc Cancer Res 46, 2473, 2005.
25. Cayen MN, Ferdinandi ES, Greselin E, and Dvornik D: Studies on the disposition of diosgenin in rats, dogs, monkeys and man. Atherosclerosis 33, 71-87, 1979.
26. Chiang HC, Tseng TH, Wang CJ, Chen CF, and Kan WS: Experimental antitumor agents from Solanum indicum L. Anticancer Res 11, 1911-1917, 1991.
27. Hu K, Dong A, Yao X, Kobayashi H, and Iwasaki S: Antineoplastic agents I: three spirostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca. Planta Med 62, 573-575, 1996.
28. Hu K, Dong A, Yao X, Kobayashi H, and Iwasaki S: Antineoplastic agents II: four furostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca. Planta Med 63, 161-165, 1997.
29. Shishodia S and Aggarwal BB: Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression. Oncogene 25, 1463-1473, 2006.
30. Hu K and Yao X: Protodioscin (NSC-698 796): its spectrum of cytotoxicity against sixty human cancer cell lines in an anticancer drug screen panel. Planta Med 68, 297-301, 2002.
31. Hu K and Yao X: The cytotoxicity of methyl protodioscin against human cancer cell lines in vitro. Cancer Invest 21, 389-393, 2003.
32. Li J, Liu X, Guo M, Liu Y, Liu S, and Yao S: Electrochemical study of breast cancer cells MCF-7 and its application in evaluating the effect of diosgenin. Anal Sci 21, 561-564, 2005.
33. Chiang CT, Way TD, Tsai SJ, and Lin JK: Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett 581, 5735-5742, 2007.
34. Sowmyalakshmi S, Ranga R, Gairola CG, and Chendil D: Effect of diosgenin (fenugreek) on breast cancer cells. Proc Amer Assoc Cancer Res 46, 5872, 2005.
35. Moalic S, Liagre B, Corbiere C, Bianchi A, Dauca M, et al.: A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells. FEBS Lett 506, 225-230, 2001.
36. Corbiere C, Liagre B, Bianchi A, Bordji K, Dauca M, et al.: Different contribution of apoptosis to the antiproliferative effects of diosgenin and other plant steroids, hecogenin and tigogenin, on human 1547 osteosarcoma cells. Int J Oncol 22, 899-905, 2003.
37. Wang SL, Cai B, Cui CB, Liu HW, Wu CF, et al.: Diosgenin-3-O-alpha-L- rhamnopyranosyl-(1 → 4)-beta-D-glucopyranoside obtained as a new anticancer agent from Dioscorea futschauensis induces apoptosis on human colon carcinoma HCT-15 cells via mitochondria-controlled apoptotic pathway. J Asian Nat Prod Res 6, 115-125, 2004.
38. Quan HJ, Koyanagi J, Komada F, and Saito S: Preparations of vitamin D analogs, spirostanols and furostanols from diosgenin and their cytotoxic activities. Eur J Med Chem 40, 662-673, 2005.
39. Raju J and Bird RP: Diosgenin, a naturally occurring furostanol saponin suppresses 3-hydroxy-3-methylglutaryl CoA reductase expression and induces apoptosis in HCT-116 human colon carcinoma cells. Cancer Lett DOI:10.1016/j.canlet.2007.04.011, 2007.
40. Liu MJ, Wang Z, Ju Y, Wong RN, and Wu QY: Diosgenin induces cell cycle arrest and apoptosis in human leukemia K562 cells with the disruption of Ca2+ homeostasis. Cancer Chemother Pharmacol 55, 79-90, 2005.
41. Leger DY, Liagre B, Cardot PJ, Beneytout JL, and Battu S: Diosgenin dose-dependent apoptosis and differentiation induction in human erythroleukemia cell line and sedimentation field-flow fractionation monitoring. Anal Biochem 335, 267-278, 2004.
42. Lee J, Jung K, Kim YS, and Park D: Disogenin inhibits melanogenesis through the activation of phosphatidylinositol-3-kinase pathway (PI3K) signalling. Life Sci DOI:10.1016/j.lfs.2007.05.009, 2007.
43. Corbiere C, Battu S, Liagre B, Cardot PJ, and Beneytout JL: SdFFF monitoring of cellular apoptosis induction by diosgenin and different inducers in the human 1547 osteosarcoma cell line. J Chromatogr B Analyt Technol Biomed Life Sci 808, 255-262, 2004.
44. Leger DY, Liagre B, Corbiere C, Cook-Moreau J, and Beneytout JL: Diosgenin induces cell cycle arrest and apoptosis in HEL cells with increase in intracellular calcium level, activation of cPLA2 and COX-2 overexpression. Int J Oncol 25, 555-562, 2004.
45. Corbiere C, Liagre B, Terro F, and Beneytout JL: Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. Cell Res 14, 188-196, 2004.
46. Leger DY, Liagre B, and Beneytout JL: Role of MAPKs and NF-kappaB in diosgenin-induced megakaryocytic differentiation and subsequent apoptosis in HEL cells. Int J Oncol 28, 201-207, 2006.
47. Liagre B, Bertrand J, Leger DY, and Beneytout JL: Diosgenin, a plant steroid, induces apoptosis in COX-2 deficient K562 cells with activation of the p38 MAP kinase signalling and inhibition of NF-kappaB binding. Int J Mol Med 16, 1095-1101, 2005.
48. Furstenberger G, Krieg P, Muller-Decker K, and Habenicht AJ: What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 119, 2247-2254, 2006.
49. Bertagnolli MM: Cox-2 and cancer chemoprevention: picking up the pieces. Recent Results Cancer Res 174, 73-78, 2007.
50. Liagre B, Vergne-Salle P, Corbiere C, Charissoux JL, and Beneytout JL: Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression. Arthritis Res Ther 6, R373-R383, 2004.
51. Liagre B, Leger DY, Vergne-Salle P, and Beneytout JL: MAP kinase subtypes and Akt regulate diosgenin-induced apoptosis of rheumatoid synovial cells in association with COX-2 expression and prostanoid production. Int J Mol Med 19, 113-122, 2007.
52. Chen X, Sood S, Yang CS, Li N, and Sun Z: Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention. Curr Cancer Drug Targets 6, 613-622, 2006.
53. Nappez C, Liagre B, and Beneytout JL: Changes in lipoxygenase activities in human erythroleukemia (HEL) cells during diosgenin-induced differentiation. Cancer Lett 96, 133-140, 1995.
54. Bermejo Benito P, Abad Martinez MJ, Silvan Sen AM, Sanz Gomez A, Fernandez Matellano L, et al.: In vivo and in vitro antiinflammatory activity of saikosaponins. Life Sci 63, 1147-1156, 1998.
55. Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7, 763-777, 2007.
56. Kridel SJ, Lowther WT, and Pemble CW IV: Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Investig Drugs 16, 1817-1829, 2007.
57. Tian WX, Li LC, Wu XD, and Chen CC: Weight reduction by Chinese medicinal herbs may be related to inhibition of fatty acid synthase. Life Sci 74, 2389-2399, 2004.
58. Rao KN: The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis. Anticancer Res 15, 309-314, 1995.
59. Cerda SR, Wilkinson J, and Broitman SA: Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines. Lipids 30, 1083-1092, 1995.
60. Caruso MG and Notarnicola M: Biochemical changes of mevalonate pathway in human colorectal cancer. Anticancer Res 25, 3393-3397, 2005.
61. Notarnicola M, Messa C, Pricci M, Guerra V, Altomare DF, et al.: Upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res 24, 3837-3842, 2004.
62. Hentosh P, Yuh SH, Elson CE, and Peffley DM: Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 32, 154-166, 2001.
63. Demierre MF, Higgins PD, Gruber SB, Hawk E, and Lippman SM: Statins and cancer prevention. Nat Rev Cancer 5, 930-942, 2005.
64. Rao CV, Newmark HL, and Reddy BS: Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. Cancer Detect Prev 26, 419-425, 2002.
65. Yang C, Yu L, Li W, Xu F, Cohen JC, et al.: Disruption of cholesterol homeostasis by plant sterols. J Clin Invest 114, 813-822, 2004.
66. Bengoechea-Alonso MT and Ericsson J: SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol 19, 215-222, 2007.
67. Schroepfer GJ: Sterol biosynthesis. Annu Rev Biochem 50, 585-621, 1981.
68. Siddals KW, Marshman E, Westwood M, and Gibson JM: Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways. J Biol Chem 279, 38353-38359, 2004.
69. Brown AJ: Cholesterol, statins and cancer. Clin Exp Pharmacol Physiol 34, 135-141, 2007.
70. Trouillas P, Corbiere C, Liagre B, Duroux JL, and Beneytout JL: Structure-function relationship for saponin effects on cell cycle arrest and apoptosis in the human 1547 osteosarcoma cells: a molecular modelling approach of natural molecules structurally close to diosgenin. Bioorg Med Chem 13, 1141-1149, 2005.
71. Kerwin SM: Soy saponins and the anticancer effects of soybeans and soy-based foods. Curr Med Chem Anticancer Agents 4, 263-272 2004.
72. Gurfinkel DM and Rao AV: Soyasaponins: the relationship between chemical structure and colon anticarcinogenic activity. Nutr Cancer 47, 24-33, 2003.